FDA Pregnancy Registry Guidance Should Stratify Drugs By Prevalence Of Use
This article was originally published in The Tan Sheet
Executive Summary
Stratification of drugs according to prevalence of use in women of childbearing age would assist industry in determining when pregnancy registries should be established, FDA's Reproductive Health Drugs Advisory Committee agreed at a meeting Oct. 18.